CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
Neoadjuvant Immunotherapy with Response-Adapted Treatment vs Standard-Of-Care Treatment For Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Selective Index Node Resection vs Lymph Node Dissection after Neoadjuvant Immunotherapy for Stage IIIB-D Melanoma The Multicentre Selective Lymphadenectomy Trial-3 (MSLT-3)
Registered participants can continue to access the Spring Meeting Virtual Event Platform to view session recordings until July 29, 2022. As you are aware, information on the Virtual Event Platform is confidential and only registered attendees who completed their confidentiality agreement can access the Virtual Event Platform (SpotMe).
Now accepting applications for the 2.5 day course developed by the Canadian Cancer Trials Group and designed for new investigators with an interest in cancer clinical research.
Currently, the majority of ovarian cancers – upwards of 75 percent – are of the subtype “high grade serous carcinoma,” which is the type being treated in this phase 2 study. While most patients with this malignant ovarian cancer subtype initially respond to standard cytotoxic therapies, more than 80 percent will relapse and succumb to the disease within five years. New treatments are urgently needed for this deadliest of gynecological cancers, which is diagnosed in more than a quarter-million women worldwide each year according to World Health Organization estimates.
Victoria Long Weekend Closure - Richardson Laboratory will be closed on May 20 (Queen’s Holiday) and May 23 (Victoria Day)
Shipment of Specimens for Banking + Kit Supply
“Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (IPROC)” (NCT04918186), is sponsored by CRI clinical partner the Canadian Cancer Trials Group (CCTG), and is open and actively recruiting patients to sites in Canada and, in the second half of 2022, will open sites in
